PRESENTATION OF RECEPTOR-CONTACTING LOOP OF HUMAN IGE ON THE HBCAG PARTICLES
Immunoglobulin of class E(IgE) plays a central role in allergies and allergic asthma. Therapeutic anti-IgE vaccine is expected to elicit autologous antibodies targeting the endogenous IgE molecules and neutralize allergic mechanism. Virus-like particles (VLPs) are a form of immunogens capable of breaking self-tolerance and represent an attractive platform for designing the therapeutic vaccines against self-antigens, such as the IgE. We designed VLPsfrom the core protein of hepatitis B virus (HBcAg). Arrays of the receptor-contacting epitopes of the human IgE were engineered on the VLP surfaces.
Objectives: Primary objective of this study was to develop IgE-epitope antigen that induces antibodies against the receptor-contacting epitope on the human IgE molecule.
Methods: Genes encoding the empty carrier and HBcAg with insertion of IgE epitope were constructed de novo and cloned into pET expression vectors. Ultracentrifugation in sucrose gradients and size exclusion chromatography (SEC) were used to purify VLPs.Electron microscopy and dynamic light scattering were used for proof of the VLPs appearance. Mice were immunized, andwestern blotswere conducted with immune sera to reveal the presence of the induced anti-(human)IgE antibodies. Titers of the anti-IgE were measured in ELISA.
Results: Two types ofplasmid constructs for expression of the VLPs carrying IgEepitope arrays were produced. One typerepresents aninsertion of an immunogenic peptide into HBcAg by construction of a contiguous fusion protein in which the peptide is flanked with sequences of the carrier. The other type is different in that the carrier protein is “split” into two polypeptide chains which upon expression remain associated in a stable VLP-forming subunit. The splitting was achieved by construction of a bicistronic RNA (s.c. “SplitCore” technology). The obtained IgE-epitope antigens with contiguous sequences appeared to be incapable of formation of VLPs. On the contrary, the split core protein efficiently formed VLPs. Immunization of mice with the VLPs presenting the IgE Cε3 FG loop resulted in the development of high titers of antibodies-recognizing human IgE in ELISA.
Conclusion: Recombinantly expressed VLPs presenting the IgE Cε3 FG loop elicitthe anti-IgE antibodies upon immunization. Application of the SplitCore technology to construct IgE-epitope antigens can result in a pan-allergy anti-IgE vaccine.
Castelli, M., Cappelletti, F., Diotti, R. A., Sautto, G., Criscuolo, E., Dal Peraro, M., & Clementi, N. (2013). Peptide-based vaccinology: experimental and computational approaches to target hypervariable viruses through the fine characterization of protective epitopes recognized by monoclonal antibodies and the identification of T-cell-activating peptides. Clinical and Developmental Immunology.doi: 10.1155/2013/521231.
Rivera-Hernandez, T., Hartas, J., Wu, Y., Chuan, Y. P., Lua, L. H., Good, M., Batzloff, M. R., & Middelberg, A. P. (2013). Self-adjuvanting modular virus-like particles for mucosal vaccination against group A streptococcus (GAS). Vaccine, 31, 1950-5. doi: 10.1016/j.vaccine.2013.02.013.
Srinivasan, A., Rastogi, A., Ayyavoo, V., & Srivastava, S. (2014). Nanotechnology-based approaches for the development of diagnostics, therapeutics, and vaccines. Monoclonal Antibodies inImmunodiagnosis and Immunotherapy, 33, 186-91.doi: 10.1089/mab.2014.0045.
Brun, A., Barcena, J., Blanco, E., Borrego, B., Dory, D., Escribano, J. M., Le Gall-Recule, G., Ortego, J.,& Dixon, L. K. (2011). Current strategies for subunit and genetic viral veterinary vaccine development. Virus Research, 157, 1-12.
Chackerian, B. (2010). Virus-like particle based vaccines for Alzheimer disease. Human Vaccines & Immunotherapeutics, 6, 926-30. doi: 10.4161/hv.7.1.12655
Whitacre, D. C., Lee, B. O., & Milich, D. R. (2009). Use of hepadnavirus core proteins as vaccine platforms. Expert Review of Vaccines, 8, 1565-73. doi: 10.1586/erv.09.121.
Newman, M., Suk, F. M., Cajimat, M., Chua, P. K., & Shih, C. (2003). Stability and morphology comparisons of self-assembled virus-like particles from wild-type and mutant human hepatitis B virus capsid proteins. Journal of Virology, 77(24), 12950-12960.
Yu, X., Jin, L., Jih, J., Shih, C., & Zhou, Z. H. (2013). 3.5A cryoEM structure of hepatitis B virus core assembled from full-length core protein. PLoS ONE, 8(9):e69729. doi: 10.1371/journal.pone.0069729.
Roose, K., De Baets, S., Schepens, B., & Saelens, X. (2013). Hepatitis B core-based virus-like particles to present heterologous epitopes. Expert Review of Vaccines, 12, 183-98.doi: 10.1586/erv.12.150.
Sabban, S. S., Ye, H., Vratimos, A., Moir, A. J., Wheeler, A. W.,& Helm, B. A. (2013). Towards a Pan-Anti-Allergy.Vaccine, 215.
Lee, J. (2014). Successful prevention of recurrent anaphylactic events with anti-immunoglobulin E therapy. Asia Pacific Allergy, 4, 126-8.doi: 10.5415/apallergy.2014.4.2.126.
Zheng, L., Li, B., Qian, W., Zhao, L., Cao, Z., Shi, S., Gao, J., Zhang, D., Hou, S., Dai, J., Wang, H., & Guo, Y. (2008). Fine epitope mapping of humanized anti-IgE monoclonal antibody omalizumab. Biochemical and Biophysical Research Communications, 375, 619-622. doi: 10.1016/j.bbrc.2008.08.055.
Klamp, T., Schumacher, J., Huber, G., Kuhne, C., Meissner, U., Selmi, A., Hiller, T., Kreiter, S., Markl, J., Tureci, O., & Sahin, U. (2011). Highly specific auto-antibodies against claudin-18 isoform 2 induced by a chimeric HBcAg virus-like particle vaccine kill tumor cells and inhibit the growth of lung metastases. Cancer Research, 71, 516-27.doi: 10.1158/0008-5472.
Wang, C. Y., Walfield, A. M., Fang, X., Hammerberg, B., Ye, J., Li, M. L., Shen, F., Shen, M., Alexander, V., & MacGlashan, D. W. (2003). Synthetic IgE peptide vaccine for immunotherapy of allergy. Vaccine, 21, 1580-1590.
Walker, A., Skamel, C., & Nassal, M. (2011). SplitCore: an exceptionally versatile viral nanoparticle for native whole protein display regardless of 3D structure. Scientific Reports, 1.doi: 10.1038/srep00005.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (Creative Commons Attribution License 3.0 - CC BY 3.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
email@example.com, www.iseic.cz, ojs.journals.cz